Royalty Pharma (RPRX) Other Operating Expenses (2019 - 2026)

Royalty Pharma has disclosed Other Operating Expenses across 8 years of filings, most recently posting -$131.8 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at -$131.8 million, down 3.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$160.9 million (down 840.84% YoY), and the FY2025 annual result was -$206.8 million, down 128.23% from the prior year.
• Other Operating Expenses came in at -$131.8 million for Q1 2026 at Royalty Pharma, down from $18.8 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $924.7 million in Q4 2022 to a low of -$227.6 million in Q3 2024.
• The 5-year median for Other Operating Expenses is $118.8 million (2023), against an average of $148.9 million.
• Peak annual rise in Other Operating Expenses reached 391.23% in 2024, while the deepest fall reached 182.13% in 2024.
• Royalty Pharma's Other Operating Expenses stood at $924.7 million in 2022, then plunged by 108.27% to -$76.5 million in 2023, then jumped by 314.39% to $164.0 million in 2024, then plunged by 88.52% to $18.8 million in 2025, then slumped by 799.47% to -$131.8 million in 2026.
• The last three Other Operating Expenses figures came in at -$131.8 million (Q1 2026), $18.8 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.